Abstract
BackgroundEpratuzumab is a humanized anti-CD22 monoclonal antibody in development for the treatment of moderate-to-severe systemic lupus erythematosus (SLE). Its efficacy in SLE has been demonstrated in three double-blind, placebo-controlled studies:...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have